Special Issue

Varicella and Zoster Vaccination

Message from the Guest Editor

In temperate climates such as the UK, many children have experienced varicella by the age of 10 years and by adulthood in excess of 90% of the population has evidence of prior VZV infection. In tropical zones, VZV infection tends to occur in individuals of older age groups. Effective vaccines are available to prevent varicella; however, uptake has been variable following concerns that varicella vaccination may result in increased cases of zoster later in life. Recently, zoster vaccines have also become available. In this Special Issue, varicella and zoster epidemiology will be addressed together with the benefits of vaccination, both in relation to differing geographical regions and in the face of new infectious challenges (SARS-CoV-2) and associations with neurological diseases.

Guest Editor

Dr. Peter Maple

1. Division of Clinical Neuroscience, Section of Clinical Neurology, University of Nottingham, Nottingham NG7 2UH, UK

2. Department of Neurology, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/195102

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

